Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667617 | SCV000792096 | likely pathogenic | Ataxia-telangiectasia syndrome | 2017-06-08 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV004555872 | SCV004167594 | uncertain significance | Lung cancer | 2023-11-20 | criteria provided, single submitter | clinical testing | This variant in ATM was detected in the blood DNA as heterozygote in a NSCLC patient. Whole exome RNA sequencing analysis conducted on a metastasized tumor specimen extracted from a non-small cell lung cancer patient, featuring 40-50% tumor content, reveals sequencing reads skipping exon 32, with an in-frame fusion of exon 31 and exon 33 providing compelling evidence for Exon Skipping event due to the germline splice acceptor variant ATM c.4612-2A>C. Therefore, we categorize this splice acceptor variant ATM c.4612-2A>C, p.? as a splice variant of uncertain significance, denoted as Class 3. |
Myriad Genetics, |
RCV004026097 | SCV004930693 | likely pathogenic | Familial cancer of breast | 2024-02-26 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. |
German Consortium for Hereditary Breast and Ovarian Cancer, |
RCV004764796 | SCV005374687 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2024-02-15 | criteria provided, single submitter | curation | According to the ClinGen ACMG ATM v1.1.0 criteria we chose these criteria: PVS1 (strong pathogenic): VCEP ATM 1.1 PVS1_str - list B, PM2 (supporting pathogenic): not found in gnomAD |